Article

Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients.

Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York 10962, USA.
Psychiatric Services (Impact Factor: 2.01). 10/2004; 55(9):1006-13. DOI: 10.1176/appi.ps.55.9.1006
Source: PubMed

ABSTRACT This study examined data on patients with serious and persistent mental illness in a large state hospital system to determine whether patients who took second-generation antipsychotics were more likely to develop diabetes mellitus than patients who took first-generation antipsychotics.
A case-control study design was used. A new prescription of an antidiabetic medication was used to identify new cases of diabetes mellitus. Odds ratios were calculated for exposure to second-generation antipsychotics (clozapine, risperidone, olanzapine, quetiapine, and multiple second-generation antipsychotics) compared with exposure to first-generation antipsychotics. Cases and controls were identified by using a database that contained drug prescription information from the inpatient facilities that were operated by the New York State Office of Mental Health. Data from January 1, 2000, to December 31, 2002, were examined. Among 13,611 unique patients who received antipsychotics, 8,461 met entry criteria of being hospitalized for at least 60 days and not having an antidiabetic medication prescribed in the past. A total of 181 of these inpatients received prescriptions for an antidiabetic medication at least 30 days after their admission. Eight controls (N=1,448) for each case (N=181) were matched by calendar year, length of observation period, race, age group, and diagnosis, giving a total sample of 1,629 patients.
Statistically significant elevations in risk were seen among patients who received more than one second-generation antipsychotic or clozapine or quetiapine, compared with patients who received first-generation antipsychotics alone. Although not statistically significant, odds ratios for olanzapine and risperidone were also elevated. Conditional logistic regression adjusting for gender and age did not change the results.
Exposure to multiple second-generation antipsychotics or clozapine or quetiapine significantly increased the risk of treatment-emergent diabetes mellitus.

0 Bookmarks
 · 
138 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The term antipsychotic polypharmacy (APP) refers to the concurrent use of two or more antipsychotic drugs in schizophrenia. The aim of this study was to investigate the range of APP in schizophrenic patients discharged from psychiatric units in Poland, and to determine its demographical and clinical correlates.
    Pharmacological reports: PR 08/2014; 66(4):613-7. · 1.97 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background The term antipsychotic polypharmacy (APP) refers to the concurrent use of two or more antipsychotic drugs in schizophrenia. The aim of this study was to investigate the range of APP in schizophrenic patients discharged from psychiatric units in Poland, and to determine its demographical and clinical correlates. Methods Data on the pharmacological treatment of 207 patients with a diagnosis of schizophrenia, discharged from six psychiatric hospitals from September–December 2011 were recorded by experienced psychiatrists. Clinical and demographical information was obtained on each patient. The severity of symptoms at admission, and their improvement during hospitalization were assessed using the Clinical Global Impression Scale. Results At discharge, 52.7% of the patients were prescribed one, 42.5% two and 4.8% three antipsychotic drugs (AP). When two AP were applied, it was usually a combination of two second generation antipsychotics (SGA) (46%), or of both first generation antipsychotics (FGA) and SGA (48%). The SGA's olanzapine and risperidone were those most commonly prescribed. Patients treated with two or more AP had a higher number of previous hospitalizations than patients receiving antipsychotic monotherapy. Mood stabilizers were prescribed for nearly one third of the patients, while antidepressants and benzodiazepines were prescribed for fewer than 10%. Conclusions The prevalence of polypharmacy in Poland is similar to that reported in other countries. This may suggest that, in a substantial proportion of schizophrenic patients clinical response to the antipsychotic monotherapy is unsatisfactory. Further studies focusing on the efficacy and safety of strategies in the treatment of patients with schizophrenia not responding to antipsychotic monotherapy are necessary.
    Pharmacological reports: PR 01/2014; 66(4):613–617. · 1.97 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In dieser Übersichtsarbeit diskutieren wir, ob es geschlechtsspezifische Unterschiede im Nebenwirkungsprofil von Antipsychotika (AP) der 2. Generation gibt. Die Ergebnisse stützen sich auf eine Medline-Suche für die Jahre 1974 bis Dezember 2005. Obwohl sich Frauen und Männer in ihrer Pharmakokinetik unterscheiden, wurden höhere Plasmaspiegel bei Frauen bisher nur für Clozapin und Olanzapin nachgewiesen. Eine Hyperprolaktinämie, die besonders unter Risperidon und Amisulprid gefunden wird, ist bei Frauen im Vergleich zu Männern stärker ausgeprägt. Die meisten Studien zeigen, dass Clozapin und Olanzapin mit der stärksten Gewichtszunahme einhergehen und dass diese bei Frauen tendenziell stärker ist. Die wenigen Studien, die es gibt, geben weiter eine höhere Prävalenz des metabolischen Syndroms bei Frauen an. Für die neueren AP gibt es sehr wahrscheinlich keine geschlechtsspezifischen Unterschiede in der Häufigkeit und Schwere von akuten oder chronischen Bewegungsstörungen. Frauen besitzen hingegen ein erhöhtes Risiko einer Störung der kardialen Repolarisation (QT-Verlängerung) mit der Gefahr von Torsades-de-Pointes-Arrhythmien unter antipsychotischer Therapie. Zusammenfassend finden sich zwar deutliche Hinweise auf geschlechtsspezifische Unterschiede im Nebenwirkungsprofil der neueren AP, doch gerade in der Beurteilung etwaiger klinischer Konsequenzen bleibt vieles zurzeit noch spekulativ. Wir benötigen prospektive Studien, die geschlechtsspezifische Aspekte als primäre Untersuchungsparameter haben, um die Bedeutung dieser Unterschiede für die Behandlung von Frauen verlässlich abschätzen zu können.
    Der Nervenarzt 01/2007; 78(1). · 0.80 Impact Factor

Full-text (2 Sources)

Download
38 Downloads
Available from
Jun 3, 2014